Fura-2-loaded human platelets were used to study Ca2+ release Furthermore, interrupting downstream receptor signalling events from intracellular compartments, as well as Ca2+ influx from the by raising intracellular levels of cyclic nucleotides (cyclic AMP, extracellular space. We investigated the response towards the cyclic GMP) again suppressed the U46619-sensitizing effect on endoperoxide/thromboxane-receptor agonist, U46619, and the thapsigargin-induced Ca2+ release. This study indicates that the inhibitor of the endoplasmic-reticulum Ca2+-ATPase, thapsiprocess of Ca2+ release followed by resequestration in response gargin. U46619 dose-dependently depleted intracellular Ca2+ to a platelet agonist by its own is not sufficient to produce the stores, followed by active sequestration of released Ca2 . Ca2+ sensitizing effect. Rather, a continuously occupied receptor influx induced by U46619 largely relies on receptor occupancy.
INTRODUCTION
compounds are useful tools with which to study intracellular Ca2+ release without involving receptor-coupled activation mechActivation of human platelets initiates an ordered sequence of anisms. events, associated with phospholipase C activation and a rapid TG and tBuBHQ have been shown to evoke Ca2+ mobilization elevation of [Ca2+] , as a major component of signal transduction [21] and Ca2+ entry in human platelets [22] . Along with our initial [1, 2] . Ca2+increase is accompanied by hydrolysis of phosphatidylobservation, further reports [23] demonstrated that platelet inositol 4,5-bisphosphate, IP3 formation, 1,2-diacylglycerol proaggregation, thromboxane formation and secretion are signifiduction, and activation of protein kinase C [3, 4] . The concerted cantly attenuated when the platelet self-amplifying eicosanoid action of these signalling events induces subsequent platelet formation is prevented. At least in human platelets, TG partially responses such as aggregation, secretion and thromboxane A2 acts as an indirect receptor agonist, as long as endoperoxide/ formation (for reviews, see [5, 6] ). Platelets show an elaborate thromboxane formation is allowed. Similar observations account mechanism of Ca2+ signalling, involvingIP3-induced mobilization for TG-elicited Ca2+ responses. TG produces an elevation of of stored Ca2+ and receptor-mediated Ca2+ entry across the cell [Ca2+]1 indistinguishable from that of a thrombin response. membrane (for reviews, see [7, 8] ). Although receptor-induced However, blocking the platelet self-amplification system [24] by Ca2+ influx has attracted ample attention regarding the channels not allowing the formation of endoperoxides/thromboxane involved, their mechanisms of activation are not fully understood (cyclo-oxygenase inhibition) or by inhibiting the endoperoxide/ (for detailed information, see [9] [10] [11] [12] [13] ). In this context the following thromboxane receptor dramatically decreases the Ca2+ traces mechanisms were suggested: first, activation of the channels by after TG addition, but not after thrombin (cyclo-oxygenase-IP3 and/or higher phosphorylation products of this initial independent concentrations) stimulation [25] . These experiments messenger; second, a G-protein-mediated coupling between the suggest the presence of at least two distinguishable types of receptor and the channel; third, a 'capacitative' link between intracellular Ca2+-storing compartments in platelets, a TGintracellular stored Ca2+ and transmembrane influx [10] . In this sensitive and a TG-insensitive Ca2+ compartment. The latter model a messenger termed CIF (Ca2+-influx factor) was proposed most probably is identical with the IP3-sensitive store. In contrast, [14] , and the involvement of GTP seems likely [15, 16] .
studies with other cells have elucidated a certain degree of iP3 [17, 18] and inhibitors of endoplasmic-reticulum ATPases overlap between the TG-sensitive and IP3-sensitive intracellular were shown to increase [Ca2+]1 in permeabilized and intact cells, stores, although cell-specific differences were reported (for respectively. TG [19] and tBuBHQ [20] cause Ca2+-store dereferences, see [8] ). Interestingly, in platelets the prior redispletion, resulting from prevention of re-uptake. Therefore, both tribution of Ca2+ by receptor agonists potentiates subsequent Ca2+ mobilization induced by TG [25] . An explanation would be that the sub-population of TG-depletable Ca2+ stores is enlarged by prior platelet activation, by diverse receptor agonists. Confirmatory results were reported by Heemskerk et al. [26] , suggesting an agonist-induced shift of Ca2+ from an agonistresponsive to a TG-sensitive intracellular store. We now extended these studies, using the stable thromboxane-receptor agonist U46619 in the absence and presence of its receptor antagonist BM13177. Focusing on intracellular Ca2+ release, our results demonstrate a strict correlation between agonist-receptor occupancy and the ability of TG to promote enhanced Ca2+ accumulation in the cytosol. Displacement of the agonist from its receptor or interruption of the receptor signalling event prevents a subsequent enlarged TG-induced [Ca2+]1 increase, although the agonist-responsive store had been discharged beforehand. We suggest an intracellular Ca2+-cycling mechanism as a result of receptor occupancy. Interference with the membrane signalling event induced by U46619 decrease the ability of TG to promote significant Ca2+ accumulation in the cytoplasmic space.
EXPERIMENTAL Materials U46619 was purchased from Paesel, Frankfurt, Germany, and thrombin was bought from Hoffmann-La Roche, Basel, Switzerland. Prostacyclin, sodium nitroprusside, ibuprofen and BW 755C were purchased from Sigma Chemie, Deisenhofen, Germany. BM13177 (sulotroban) was delivered by Boehringer Mannheim, Mannheim, Germany. Tg was obtained from Gibco, Eggenstein, Germany. All other materials were as previously described [25] or were obtained in the highest grade of purity available from local commercial sources.
Preparation of platelet-rich plasma and washed human platelets Platelet-rich plasma (PRP) and suspensions of washed human platelets were mainly prepared as previously outlined [25] . Briefly, fresh human blood was anticoagulated by using trisodium citrate (0.38 %, w/v) and PRP resuspended in the buffer described above. Changes in fluorescence of the fura-2-loaded platelets at the excitation wavelengths of 335 and 362 nm and emission wavelengths above 450 nm were determined after addition of antagonists and agonists by using a Sigma ZWS-II dual-wavelength spectrofluorimeter (Biochem, Puchheim, Germany). The ratio of the fluorescence is a measure of platelet [Ca2l] , [27] . The ratios of maximum and minimum fluorescence were determined by addition of 250 ,uM digitonin in the presence of 1 mM free Cal and in the presence of 10 mM EGTA (pH > 8. 5 These were carried out in intact platelets as stated in [25] . When necessary, external Ca2' was removed by adding 0.5 mM EGTA. For the Ca2+-overshoot experiments, the indicated concentration of free Ca2+ was added at the end of the experiment as described in the individual Figures 
Figure 6 Ca2+ movements induced by U46619, TG and BM13177
Calcium measurements were done as outlined in Figure 5 . Figure 6 describes the situation when platelets were stimulated by the protocol employed in Figure 5 (Figure 7 , trace 2). The Ca2+ levels at the end of these manipulations were nearly identical. Although TG-induced Ca2+ release was transient in platelets treated in the presence of EGTA, compared with a more sustained response when measured in a nominally Ca2+-free solution, the overall effect of BM13177 remained the same.
To exclude non-specific effects of BM 13177, we investigated its action in similar experiments, using thrombin instead of U46619 as the sensitizing agonist. BM13177 had no effect on thrombin- evoked Ca2+ signals, nor did it interfere with the sensitizing potency of thrombin concerning subsequent TG-induced Ca2+ accumulation, when thrombin concentrations above 0.1 unit/ml were used; i.e. cyclo-oxygenase-independent activation mechanism (results not shown). Thus its effects were considered specific to modulation of thromboxane/endoperoxide-receptor function.
Intervention by cyclic nucleotides
The experiments described above demonstrated that sustained receptor occupancy seems to be required for potentiation of TGevoked Ca2+ accumulation. Besides receptor antagonists, cyclic nucleotides are known to inhibit receptor-mediated signalling events in human platelets (see [8] for references). Sodium nitroprusside causes an intra-platelet cGMP increase, whereas prostacylin stimulates cAMP production in thrombocytes. Inhibition of the phosphatidylinositol response after receptor occupancy is a common target of both cGMP as well as cAMP. Taking this action into consideration, we also used either of the above-mentioned cyclic-nucleotide-increasing compounds instead of BM13177. We were interested to see whether they interfered with the signalling events that cause potentiated TGinduced Ca2+ accumulation (Figure 8) (Figure 8 ) was identical with the action of BM13177 ( Figure 5 ) in modulating a TG response followed by receptor stimulation.
We expected increased levels of cyclic nucleotides to be effective also in preventing thrombin-evoked potentiation of TG-induced Ca2+ accumulation, in contrast with the thromboxane/ endoperoxide-receptor antagonist. Indeed, in an experimental set-up similar to that described in Figure 8 , increased cyclic nucleotide levels partially suppressed the sensitizing effect of thrombin (0.07 unit/ml) when given beforehand in place of U46619 (results not shown).
DISCUSSION
Human platelets, while activated, liberate Ca21 from intracellular stores and show Ca2+ influx from the extracellular space [1, 7] . Weak agonists rely on the formation of thromboxane in order to cause full aggregation [6] . Therefore, the stable thromboxanereceptor agonist U46619, binding to the endoperoxide/ thromboxane receptor, can substitute for thromboxane A2 to elicit platelet activation. Application of U46619 resulted in an immediate and substantial elevation of [Ca2+] . In another experimental approach we studied Ca2+ entry by measuring the [Ca2+], response upon restoration of extracellular [Ca2+] in platelets that were depleted of the agonist-sensitive Ca2+ store by a preceding stimulation with U46619 (Figures 1 and 2) . Interestingly, for U46619 to cause considerable Ca2+ influx a sustained receptor occupancy seems necessary. Replacement of U46619 from its receptor before restoration of extracellular [Ca2+] or elevating intracellular levels of cyclic nucleotides blunted Ca2+ entry. This leads into the ongoing discussion of how Ca2+ entry is regulated. For platelets, both store-dependent 'capacitative' Ca2+ influx and receptor-dependent mechanisms have been revealed [29] [30] [31] . Similar mechanisms operate in other cells, for example in PC-12 cells [32] or Jurkat T cells [33] . Since it was reported that both regulatory mechanisms may control distinct channels with differential cation selectivity [34, 24] , we decided to rely on Ca2+-overshoot studies rather than on Mn2+ influx, for correct measurement of Ca2+ entry.
Our results indicated that Ca2+ entry in response to U46619 mainly demands receptor occupancy. In contrast with the 'capacitative model', where parotid cells stimulated with methacholine followed by the addition of the receptor antagonist atropine still show substantial Ca2+ entry [10] , in human platelets the signal for Ca2+ entry was blunted after replacement of the agonist U46619 by BM13177. Thus the signal for Ca2+ entry in human platelets in response to U46619 must be somehow controlled by the occupied receptor. The existence of such a receptor-regulated Ca2+-entry pathway became evident from other studies using angiotensin II-stimulated adrenal glomerulosa cells, in which Ca2+ pools had been emptied beforehand. After readdition of Ca2+, a significant increase in the amplitude and the rate of the rise in [Ca2+]2 was seen in agonist-stimulated compared with unstimulated controls [35] . Evidently, Ca2+ entry by receptor-operated channels would be one explanation for the observed effect in platelets. However, if there is a role of store depletion in control of Ca2+ entry, then this regulatory link is again gated by the activated receptor. For exact evaluation of the role ofstore depletion in regulation ofCa2+ entry, an experimental set-up would be necessary in which Ca2`release from the regulating store is blocked without interference by other receptormediated signalling events. Such a system is currently not available for human platelets.
Thapsigargin, a Ca2+-ATPase inhibitor, completely inhibits all known isoforms of the sarcoplasmic/endoplasmic-reticulum Ca2+-ATPases [36] . Treatment [21, 37] . Moreover, TG-evoked responses were potentiated by pre-activation of platelets with thrombin, ADP, ionomycin and thimerosal [25, 26] . The magnitude and rapidity of this effect suggests that the Ca2+ signals produced by agonists and TG synergize, in such a way that TG acts more efficiently when agonist-sensitive stores were depleted before TG application (Figure 3) . The data point to a mechanism involving Ca2+ transport from TG-insensitive to TG-sensitive Ca2+ stores. A functional heterogeneity within intracellular Ca2+ pools [38] might also be explained by distinct sequestering and releasing compartments within the IP3-sensitive Ca2+ pool. For RINm5F cells it has been proposed that TG quickly mobilized Ca2+ from the sequestering compartment, whereas Ca2+ from the releasing compartment could be mobilized only very slowly, in the absence ofIP3 [39] . Other studies using platelet mixed membranes revealed a complete overlap of the TG-sensitive and the IP3-sensitive Ca2+ pool, although in intact cells a functional heterogeneity became evident, indicating agonist utilization of a Ca2+-ATPaseinhibitor-insensitive pool [40] . With this study we intend to suggest an explanation of these contradictory findings that involves a fast cycling of large quantities of intracellular Ca2+ between sequestering and releasing Ca2+ compartments. As previously shown by different laboratories using thrombin [25, 26] analogy with coupling of the depleted agonist-sensitive store with plasma-membrane Ca2+ entry. Intriguingly, Ca2+ cycling and Ca2+ entry were found to be regulated exactly in parallel. After IP3-mediated release ofits stored Ca2+, the agonist-sensitive store may couple not only with the extracellular Ca2+ compartment, but also in a similar way with the TG-sensitive intracellular Ca2+-storing compartment. This coupling then enables Ca2+ entry and cycling of intracellular Ca2+. To maintain this coupling, a so-far unknown signalling event from the activated receptor is required. One can speculate about the involvement of GTP or perhaps small G-proteins. Conceivably, the termination of this signal causes closing of Ca2+ channels in the agonistsensitive compartment, leading to its refilling and uncoupling from the other compartments.
